Hapoalim Upgrades Teva

Bank Hapoalim upgraded its recommendation for Teva Pharmaceutical Industries Ltd. from “Market perform” to “Outperform” and raised its target price from $47 to $50. The new target is 31.5% above Teva’s closing price of $42.49 on Nasdaq.
Globes